장대영 교수
fhdzang@hallym.or.kr
전문진료분야
위·대장·간·췌장·담도·GIST 소화기암, 만성백혈병·골수이형성증 등 혈액질환
전화 예약
1577-1801
기본정보
학력
한림대학교 의과대학 의학박사(MD, Ph.D) |
경력
현) 한림대학교의료원 중앙임상의학연구소 소장 현) 한림대학교성심병원 임상시험센터장 Weil Cornell Cancer Center, New York, USA, Visiting Professor FHCRC, Research Associate, Seattle, USA 서울아산병원 종양혈액내과 임상강사 |
학회활동
현) 대한항암요법연구회(KCSG) 회장, 이사회의장 현) 대한임상시험센터협의회(KACTC) 회장 대한위암학회 현)상임이사 대한종양내과학회 현)윤리위원장, 기획이사 대한혈액학회 교육수련이사, 사회봉사교육이사 과기부 생명공학연구원 현)바이오규제위원 국가항암신약개발사업단 현)자문위원 국민건강보험공단 현)약제급여평가위원, 현)산정특례위원 대한암학회 건강보험정책위원장 식품의약품안전처 현)항암제전략자문위원, 현)중앙약사심의위원, 현)심속심의자문위원 건강보험심사평가원 현)암질환심의위원 |
수상이력
미국혈액학회 우수논문상 한림대학교 학술상 |
논문
Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study (Journal of Clinical Oncology)
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10) (Cancer Research and Treatment)
AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20) (Oncologist)
Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer (JOURNAL OF CLINICAL ONCOLOGY)
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group (vol 54, pg 1, 2022) (CANCER RESEARCH AND TREATMENT)
Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE) (CANCER MEDICINE)
Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen (JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY)
RNF43 R117fs mutant positively regulates Wnt/β-catenin signaling by failing to internalize FZD expressed on the cell surface (Scientific Reports)
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer (Nature Communications)
Oxaliplatin (3 months v 6 months) with 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients with Stage II/III Colon Cancer: KCSG CO09-07 (Journal of Clinical Oncology)
위암 임상진료지침 (한국임상암학회)
위암표준진료권고안 (대한의학회)
환우와 가족을 위한 혈액 질환 소개서 (대한혈액학회)
혈액학 / Hematology ((주)범문에듀케이션)
RECTAL CANCER-a multidisciplinary approach to management (Intech)
혈액학 / hematology (E*public)
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10) (Cancer Research and Treatment)
AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20) (Oncologist)
Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer (JOURNAL OF CLINICAL ONCOLOGY)
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group (vol 54, pg 1, 2022) (CANCER RESEARCH AND TREATMENT)
Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE) (CANCER MEDICINE)
Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen (JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY)
RNF43 R117fs mutant positively regulates Wnt/β-catenin signaling by failing to internalize FZD expressed on the cell surface (Scientific Reports)
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer (Nature Communications)
Oxaliplatin (3 months v 6 months) with 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients with Stage II/III Colon Cancer: KCSG CO09-07 (Journal of Clinical Oncology)
위암 임상진료지침 (한국임상암학회)
위암표준진료권고안 (대한의학회)
환우와 가족을 위한 혈액 질환 소개서 (대한혈액학회)
혈액학 / Hematology ((주)범문에듀케이션)
RECTAL CANCER-a multidisciplinary approach to management (Intech)
혈액학 / hematology (E*public)